<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04255875</url>
  </required_header>
  <id_info>
    <org_study_id>C4071001</org_study_id>
    <nct_id>NCT04255875</nct_id>
  </id_info>
  <brief_title>Dose Escalation Study of PF-07209326 in Healthy Participants and Participants With Sickle Cell Disease</brief_title>
  <official_title>A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED EVALUATION OF SINGLE DOSES OF PF-07209326 IN HEALTHY PARTICIPANTS (SAFETY, TOLERABILITY, AND PHARMACOKINETICS [PK]) FOLLOWED BY AN OPEN LABEL, REPEAT DOSE EVALUATION IN SICKLE CELL DISEASE PARTICIPANTS (SAFETY, TOLERABILITY, PK AND EFFICACY)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This Phase 1 first-in-human, first-in-patient, single ascending dose and multiple dose study&#xD;
      will be a randomized, double-blind, placebo-controlled investigation of the safety,&#xD;
      tolerability, and pharmacokinetics of PF-07209326 in healthy participants and participants&#xD;
      with sickle cell disease.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Part 1 will evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of&#xD;
      single ascending doses of PF-07209326 delivered by subcutaneous injection or intravenous&#xD;
      delivery in healthy volunteer participants. After establishing the safety and tolerability in&#xD;
      healthy participants, Part 2 will evaluate the safety and tolerability, pharmacokinetics and&#xD;
      pharmacodynamics of subcutaneously delivered multiple dose of PF-07209326 in participants&#xD;
      with sickle cell disease.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 5, 2020</start_date>
  <completion_date type="Anticipated">February 18, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 18, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Masking will only be applicable to Part 1 of the study where Healthy participants will be enrolled and randomized to receive either PF-07209326 or to placebo. In Part 2 of the study, all eligible SCD participants will receive PF-07209326 and no masking will be required.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs</measure>
    <time_frame>Day 1 up to Day 85 (SAD) or Day 113 (MD)</time_frame>
    <description>Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with laboratory abnormalities</measure>
    <time_frame>Day 1 up to Day 85 (SAD) or Day 113 (MD)</time_frame>
    <description>Percentage of subjects with laboratory abnormalities</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with change from baseline in vital signs</measure>
    <time_frame>Day 1 up to Day 85 (SAD) or Day 85 (MD)</time_frame>
    <description>blood pressure, pulse rate, temperature, respiration rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with change from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Day 1 up to Day 85 (SAD) or Day 85 (MD)</time_frame>
    <description>Number of subjects with change from baseline in electrocardiogram (ECG) parameters</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with injection site reactions</measure>
    <time_frame>Day 1 up to Day 11 post (SAD) Day 1 up to Day 85 (MD)</time_frame>
    <description>Percentage of subjects with injection site reactions</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with infusion site reactions</measure>
    <time_frame>Day 1 up to Day 11 post each dose (SD)</time_frame>
    <description>Percentage of subjects with infusion site reactions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK /Cmax</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Maximum serum concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / DN Cmax</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Dose normalized Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / Tmax</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Time for Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / AUClast</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Area under the serum concentration time profile from time zero to the time of the last quantifiable concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / DN AUClast</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Dose normalized AUClast</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / AUCinf</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Area under the serum concentration time profile from time zero to infinity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / DN AUCinf</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Dose normalized AUCinf.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / t½</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Terminal half life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / CL (IV only)</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / CL/F (SC only)</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Apparent clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / Vss (IV only)</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Volume of distribution at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / Vz/F (SC only)</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Apparent volume of distribution at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD: Single Dose PK / F (SC only)</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Apparent bioavailability</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD: AUCtau</measure>
    <time_frame>Day 1 up to Day 22</time_frame>
    <description>Area under the curve over the dosing interval tau (1 week) after the first and last doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SAD:ADA and/or NAb</measure>
    <time_frame>Day 1 up to Day 85</time_frame>
    <description>Frequency of anti-drug antibody (ADA) and/or neutralizing antibody (NAb) productions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MD:ADA and/or NAb</measure>
    <time_frame>Day 1 up to Day 113</time_frame>
    <description>Frequency of anti-drug antibody (ADA) and/or neutralizing antibody (NAb) productions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported VOC event rate and VOC day rate</measure>
    <time_frame>Day 1 to 85</time_frame>
    <description>Efficacy in SCD participants based on an electronic patient reported outcome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">54</enrollment>
  <condition>Healthy</condition>
  <condition>Sickle Cell Anemia</condition>
  <arm_group>
    <arm_group_label>Treatment Healthy Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive single ascending doses of subcutaneous (SC) or intravenous PF-07209326</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Healthy Participants</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will receive matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment for SCD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive a multiple dose of subcutaneous PF-07209326</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive matching placebo</description>
    <arm_group_label>Placebo Healthy Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-07209326</intervention_name>
    <description>Participants will receive SC or IV single ascending doses</description>
    <arm_group_label>Treatment Healthy Participants</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-07209326</intervention_name>
    <description>SCD participants will receive a multiple dose of subcutaneous PF-07209326</description>
    <arm_group_label>Treatment for SCD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Health Participants:&#xD;
&#xD;
        1. Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs).&#xD;
&#xD;
        Exclusion Criteria Healthy Participants:&#xD;
&#xD;
          1. Evidence or history of clinically significant hematological, renal, endocrine,&#xD;
             pulmonary, gastrointestinal, immunocompromised (or known disorder of the immune&#xD;
             system), cardiovascular, hepatic, psychiatric, neurological, or allergic disease&#xD;
             (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies&#xD;
             at the time of dosing).&#xD;
&#xD;
          2. History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis C;&#xD;
             positive testing for HIV, hepatitis B surface antigen (HBsAg), hepatitis B core&#xD;
             antibody (HBcAb), or hepatitis C antibody (HCVAb). Hepatitis B vaccination is allowed.&#xD;
&#xD;
          3. History of active or latent tuberculosis (TB) regardless of treatment or positive&#xD;
             QuantiFeron TB test.&#xD;
&#xD;
          4. Participants with any of the following acute or chronic infections or infection&#xD;
             history:&#xD;
&#xD;
               -  Any infection requiring treatment within 2 weeks prior to the screening visit.&#xD;
&#xD;
               -  Any infection requiring hospitalization, parenteral antimicrobial therapy within&#xD;
                  30 days of the first dose of investigational product.&#xD;
&#xD;
               -  Any infection judged to be an opportunistic infection, within the past 6 months&#xD;
                  of the first dose of the investigational product.&#xD;
&#xD;
               -  Known active or history of frequent bacterial, viral, fungal, mycobacterial or&#xD;
                  other infections as determined by the PI.&#xD;
&#xD;
               -  Participants with a fever within the last 7 days prior to dosing.&#xD;
&#xD;
          5. Participants with a history of allergic or anaphylactic reaction to therapeutic or&#xD;
             diagnostic protein.&#xD;
&#xD;
          6. Other acute or chronic medical or psychiatric condition including recent (within the&#xD;
             past year) or active suicidal ideation or behavior or laboratory abnormality that may&#xD;
             increase the risk associated with study participation or investigational product&#xD;
             administration or may interfere with the interpretation of study results and, in the&#xD;
             judgment of the investigator, would make the participant inappropriate for entry into&#xD;
             this study.&#xD;
&#xD;
        Inclusion Criteria for SCD Participants&#xD;
&#xD;
          1. Participants between the ages of 18 and 65 years old with a confirmed diagnosis of&#xD;
             stable sickle cell disease (HbSS or HBS β0 thalassemia).&#xD;
&#xD;
          2. Medical history of ≥2 and ≤ 10 medical utilization VOCs in 12 months prior to&#xD;
             screening.&#xD;
&#xD;
          3. ≥75% of daily ePRO diary completion, over a minimum of 14 days during the screening&#xD;
             period.&#xD;
&#xD;
          4. Fully vaccinated for COVID-19 in accordance with the Center for Disease Control&#xD;
             guidance prior to Screening or must be negative for SARS-CoV-2 by polymerase chain&#xD;
             reaction (PCR) within 72 hours of the Day 1 visit.&#xD;
&#xD;
          5. Body Mass Index (BMI) ≤34.9 kg/m2 and weight ≥50 kg.&#xD;
&#xD;
        Exclusion Criteria for SCD Participants&#xD;
&#xD;
          1. Evidence or history of clinically significant hematological (non-SCD), renal,&#xD;
             endocrine, pulmonary, gastrointestinal, cardiovascular (including overt stroke but&#xD;
             excluding silent infarct), hepatic (excluding cholelithiasis), psychiatric,&#xD;
             neurological, or allergic disease (including drug allergies, but excluding untreated,&#xD;
             asymptomatic, seasonal allergies at the time of dosing).&#xD;
&#xD;
          2. Evidence or history of cardiac disease includes myocardial infarction, clinically&#xD;
             significant cardiac arrhythmia (eg, atrial fibrillation, paroxysmal atrial&#xD;
             fibrillation, atrial flutter, supraventricular tachycardia, and ventricular&#xD;
             tachycardia), left ventricular failure, unstable angina, and coronary artery bypass&#xD;
             grafting.&#xD;
&#xD;
          3. History of cancer (other than cutaneous basal cell or carcinoma in-situ) in the&#xD;
             previous 5 years.&#xD;
&#xD;
          4. Active infection with Hepatitis B or C or HIV. Individuals seropositive for infection&#xD;
             with Hepatitis C must be negative for viral RNA by PCR on at least 2 determinations.&#xD;
&#xD;
          5. History of active or latent tuberculosis (TB) regardless of treatment or positive&#xD;
             QuantiFeron TB test.&#xD;
&#xD;
          6. Major surgery &lt;3 months prior to baseline or planned significant medical procedures&#xD;
             during the study.&#xD;
&#xD;
          7. Participants with any of the following acute or chronic infections or infection&#xD;
             history:&#xD;
&#xD;
               -  Any infection requiring treatment within 2 weeks prior to the screening visit.&#xD;
&#xD;
               -  Any infection requiring hospitalization, parenteral antimicrobial therapy within&#xD;
                  30 days of the first dose of investigational product.&#xD;
&#xD;
               -  Any infection judged to be an opportunistic infection, within the past 6 months&#xD;
                  of the first dose of the investigational product.&#xD;
&#xD;
               -  Known active or history of frequent bacterial, viral, fungal or other infections&#xD;
                  as determined by the Investigator.&#xD;
&#xD;
               -  Participants with a fever within the last 7 days prior to dosing.&#xD;
&#xD;
          8. Evidence or history of clinically significant orthostatic blood pressure changes.&#xD;
&#xD;
          9. Other acute or chronic medical or psychiatric condition that may increase the risk&#xD;
             associated with study participation or investigational product administration or may&#xD;
             interfere with the interpretation of study results and, in the judgment of the&#xD;
             investigator, would make the participant inappropriate for entry into this study.&#xD;
&#xD;
         10. Participants with a history of allergic or anaphylactic reaction to therapeutic or&#xD;
             diagnostic protein.&#xD;
&#xD;
         11. History of sensitivity to heparin or heparin induced thrombocytopenia.&#xD;
&#xD;
         12. Administration of voxelotor within 4 weeks prior to screening or planned use during&#xD;
             the study.&#xD;
&#xD;
         13. Administration of crizanlizumab within 12 weeks prior to screening or planned use&#xD;
             during the study.&#xD;
&#xD;
         14. Planned transfusion during the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New Haven Clinical Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Research LLC dba Nucleus Network</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=C4071001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>February 3, 2020</study_first_submitted>
  <study_first_submitted_qc>February 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 5, 2020</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <keyword>Single ascending dose</keyword>
  <keyword>Multiple dose</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Phase 1</keyword>
  <keyword>First in human</keyword>
  <keyword>First in patient</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

